Author:
Lunnon Martin W.,Wallace Sharon M. L.,Palmer Joanne E.,Francis-Lang Andrew,Laurijssens Bart E.,Mistry Prafull,Albala Bruce,Nagafuji Toshiaki,Wilkinson Ian B.,Maltby Kay
Subject
Pharmacology (medical),Pharmacology
Reference16 articles.
1. Endothelin receptor antagonists. Promising new agents in the management of cardiovascular disorders;Goddard;Drugs R D,1999
2. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonists in heart failure?;Kalra;Int J Cardiol,2002
3. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial;Anand;Lancet,2004
4. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomised, double blind, placebo controlled, multicenter Phase IIa study;Vajkoczy;J Neurosurg,2005
5. Pharmacological characterization of a potent nonpeptide endothelin receptor antagonist, 97-139;Mihara;J Pharmacol Exp Ther,1994
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Drug code names and other ethics-related matters;British Journal of Clinical Pharmacology;2010-03